Abstract
The removal of urokinase from the market has created a dilemma for interventionists and vascular surgeons treating patients with acute limb threatening ischemia due to arterial thrombosis or embolization. Reteplase is a newer, fibrin-specific thrombolytic agent with properties that make it an attractive alternative to urokinase. We report two cases of successful treatment of acute, limb threatening ischemia with intra-arterial Reteplase therapy.
MeSH terms
-
Acute Disease
-
Aged
-
Angiography
-
Fibrinolytic Agents / administration & dosage*
-
Foot / blood supply*
-
Humans
-
Infusions, Intra-Arterial
-
Ischemia / diagnostic imaging
-
Ischemia / drug therapy*
-
Male
-
Middle Aged
-
Recombinant Proteins / administration & dosage*
-
Thrombolytic Therapy / methods
-
Tissue Plasminogen Activator / administration & dosage*
Substances
-
Fibrinolytic Agents
-
Recombinant Proteins
-
reteplase
-
Tissue Plasminogen Activator